WHO ICTRP trial
The effects of RNS60 on ALS biomarkers
EUCTR2016-002382-62-IT · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2016-002382-62-IT |
|---|---|
| Public title | The effects of RNS60 on ALS biomarkers |
| Scientific title | The effects of RNS60 on ALS biomarkers - RNS60-ALS |
| Primary sponsor | IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | United States;Italy |
| Conditions | Amyotrophic Lateral Sclerosis MedDRA version: 21.1 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 21.1 Level: LLT Classification code… |
| Interventions | Product Name: RNS60 Product Code: RNS60 Pharmaceutical Form: Solution for infusion Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Name: RNS60 Product Code: RNS60… |
| Registration date | Jun 22, 2021 |
| Target size | 142 |
| Secondary IDs | RNS60-ALS |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: